Mapping the patient journey has become more complex, but also more critical to understand what is actually happening in the treatment or therapeutic landscape. This webinar will explore how leveraging PurpleLab’s integrated data sources, including claims and Social Determinants of Health (SDOH), can unlock critical insights for commercial, market access, and medical affairs teams.

Alzheimer’s disease (AD) is a complex and heterogeneous condition requiring early detection and intervention. Biomarkers contribute to diagnostic processes and real-world evidence (RWE) outcomes. Robust real-world data can drive insights to bridge disease, policy, clinical trials, and access gaps in the diagnosis and treatment of AD, providing valuable objective endpoints.

Enhance clinical trial development with PurpleLab’s data-driven insights. ​ Access patient-level data, optimize trial design, improve recruitment, and generate real-world evidence.

Launching a new pharmaceutical product is a high-stakes endeavor, with nearly 40% of launches failing to meet expectations. To improve these odds, companies must shift to a data-driven approach, leveraging real-world insights to engage decision-makers effectively across the patient journey.

This case study explores how a pharmaceutical company successfully planned and executed a Phase III clinical trial for a new oncology drug.

Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge. In a new webinar, sponsored by PurpleLab, experts explore how PurpleLab’s data solutions can help foster a deeper understanding of physician prescribing behavior.

When evaluating a data partner, make sure you are choosing a trusted data partner that meets all your needs. This handy dandy checklist can help ensure that you’re selecting a trusted data partner.

Learn more about what PurpleLab can do for Clinical Trials Life Sciences Download

More than a year has passed since Humira biosimilars were launched in the US, and with these, several other biosimilar drug approvals that either directly compete with Humira or are indicated for other rare immunologic conditions, macular degeneration, and oncology and hematological disease.  Ongoing industry surveillance of biosimilars and the   Source: “Biosimilars are becoming more widely available,…